AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16679989 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (device turned off)
Number of subjects: 10
Study 15621120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1000 mg twice a day with stepwise reduction of CNI
Number of subjects: 32
Study 15621120 — intervention group
Group type: COMPARATOR
Intervention: Continue current CNI dose
Number of subjects: 32
Study 11273951 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IM (Group K)
Number of subjects: 30
Study 11273951 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 30
Study 9678092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐dose, gestodene‐containing triphasic oral contraceptive
Number of subjects: 20
Study 8388583 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (EN) 40 mg
Number of subjects: 12
Study 8388583 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (EN) 1 mg kg‐1
Number of subjects: 12
Study 8388583 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5,000 IU
Number of subjects: 12
Study 28624553 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg daily for 8 weeks
Number of subjects: 94
Study 28624553 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 75 mg daily for 8 weeks
Number of subjects: 94
Study 26832834 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD+CAF
Number of subjects: 3
Study 26832834 — intervention group
Group type: COMPARATOR
Intervention: CTG+CAF
Number of subjects: 3
Study 23879344 — intervention group
Group type: EXPERIMENTAL
Intervention: Angled interdental brushes
Number of subjects: 128
Study 23879344 — intervention group
Group type: COMPARATOR
Intervention: Straight interdental brushes (standard control)
Number of subjects: 128
Study 22516884 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy (n = 37)
Number of subjects: 79
Study 22516884 — intervention group
Group type: COMPARATOR
Intervention: Pain-management program without horticultural therapy (control, n = 42)
Number of subjects: 79
Study 20189239 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting
Number of subjects: 1713
Study 20189239 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 1713
Study 18471665 — intervention group
Group type: EXPERIMENTAL
Intervention: $4 instant lottery ticket incentive (Group A)
Number of subjects: 728
Study 18471665 — intervention group
Group type: COMPARATOR
Intervention: No incentive (Group B)
Number of subjects: 728
Study 15735918 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 14
Study 14628714 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node navigation surgery (SNNS)
Number of subjects: 0
Study 10813593 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding bradycardia group (12 infants)
Number of subjects: 12
Study 10813593 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 infants)
Number of subjects: 12
Study 8659720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group 1, n = 25)
Number of subjects: 100
Study 8659720 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 2.5 mg with induction of anesthesia and 1.25 mg 12 h later (Group 2, n = 25)
Number of subjects: 100
Study 8659720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg with induction (Group 3, n = 25)
Number of subjects: 100
Study 8659720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron plus droperidol at the same doses as Groups 3 and 2 (Group 4, n = 25)
Number of subjects: 100
Study 1899945 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 204
Study 1899945 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 204
Study 6507997 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms/day)
Number of subjects: 37
Study 6507997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31146138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 36
Study 31146138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 29292694 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg multiunit pellet system (MUPS) tablets
Number of subjects: 60
Study 29292694 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg banded capsules
Number of subjects: 60
Study 26895919 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction phase (pager beeped and questions asked)
Number of subjects: 30
Study 26895919 — intervention group
Group type: COMPARATOR
Intervention: Quiet phase (uninterrupted task performance)
Number of subjects: 30
Study 24965218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (NSPT)
Number of subjects: 40
Study 24965218 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI)
Number of subjects: 40
Study 24965218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy (NSPT) and Oral hygiene instructions (OHI)
Number of subjects: 40
Study 21953573 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 20 mg
Number of subjects: 12
Study 21953573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20470423 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling
Number of subjects: 128
Study 20470423 — intervention group
Group type: COMPARATOR
Intervention: Individual counseling
Number of subjects: 128
Study 17701044 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral ultrasonography-guided injections of autologous myoblasts and fibroblasts
Number of subjects: 63
Study 17701044 — intervention group
Group type: COMPARATOR
Intervention: Transurethral endoscopic injections of collagen
Number of subjects: 63
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mean weighted quality score
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate controls
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussions of side effects
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization blinding
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding observers to results
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-beta estimates
Number of subjects: 0
Study 15920210 — intervention group
Group type: EXPERIMENTAL
Intervention: Absence of important pretreatment clinical predictors
Number of subjects: 0
Study 11893435 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal supplementation of antioxidant vitamins (beta-carotene 20 mg, vitamin E 167.8 mg, vitamin C 1000 mg daily until delivery)
Number of subjects: 5
Study 11893435 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 mother-infant pairs comparable in gestation and birthweight)
Number of subjects: 5
Study 9451067 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow rate (200 ml/min)
Number of subjects: 20
Study 9451067 — intervention group
Group type: COMPARATOR
Intervention: Low flow rate (100 ml/min)
Number of subjects: 20
Study 8560537 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-amoxiclav
Number of subjects: 101
Study 8560537 — intervention group
Group type: COMPARATOR
Intervention: Oral 'conventional' regimen (combination of chloramphenicol, cotrimoxazole, and doxycycline)
Number of subjects: 101
Study 2172402 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 60
Study 2172402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 60
Study 2172402 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 60
Study 2172402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 845296 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured learning sessions designed to teach interviewee verbal skills
Number of subjects: 40
Study 845296 — intervention group
Group type: COMPARATOR
Intervention: Time and attention placebo procedure
Number of subjects: 40
Study 31345778 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg norursodeoxycholic acid
Number of subjects: 198
Study 31345778 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg norursodeoxycholic acid
Number of subjects: 198
Study 31345778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 29896930 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (L‐[2,3,3,4,5,5,5,6,6,6‐2 H10 ]leucine at 0.15 μmol/kg fat‐free mass/min)
Number of subjects: 20
Study 29896930 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 20
Study 29896930 — intervention group
Group type: COMPARATOR
Intervention: Fasted state
Number of subjects: 20
Study 26906703 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted cataract surgery
Number of subjects: 314
Study 26906703 — intervention group
Group type: COMPARATOR
Intervention: Conventional phacoemulsification cataract surgery
Number of subjects: 314
Study 23570672 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 0
Study 21553314 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandaging
Number of subjects: 21
Study 21553314 — intervention group
Group type: COMPARATOR
Intervention: Compression garments
Number of subjects: 21
Study 21028969 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg of elemental zinc daily for 8 weeks)
Number of subjects: 60
Study 21028969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17318893 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat tibial insert
Number of subjects: 53
Study 17318893 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial insert
Number of subjects: 53
Study 17318893 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) insert
Number of subjects: 53
Study 17318893 — intervention group
Group type: EXPERIMENTAL
Intervention: Concave tibial insert with resection of the posterior cruciate ligament
Number of subjects: 53
Study 16883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Shizhang Cataplasm (SC) for excessive syndrome (ES) type
Number of subjects: 77
Study 16883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuzhang Cataplasm (XC) for deficient syndrome (DS) type
Number of subjects: 77
Study 16883906 — intervention group
Group type: COMPARATOR
Intervention: Control group for excessive syndrome (ES) type
Number of subjects: 77
Study 16883906 — intervention group
Group type: COMPARATOR
Intervention: Control group for deficient syndrome (DS) type
Number of subjects: 77
Study 16883906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SC and XC
Number of subjects: 77
Study 12008859 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra 30 to 150 mg subcutaneously each day for 24 weeks
Number of subjects: 0
Study 12008859 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 25 mg subcutaneously twice weekly
Number of subjects: 0
Study 12008859 — intervention group
Group type: COMPARATOR
Intervention: Infliximab 3 to 10 mg/kg intravenously every 4 or 8 weeks
Number of subjects: 0
Study 10594397 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 1351
Study 10594397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 1351
Study 8838789 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute pain syndromes
Number of subjects: 49
Study 8838789 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain syndromes
Number of subjects: 49
Study 8838789 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific pain types (tension and pain in extremities, spasms, low back pain, Lhermitte's sign, neuralgia)
Number of subjects: 49
Study 8838789 — intervention group
Group type: EXPERIMENTAL
Intervention: Deterioration of disability
Number of subjects: 49
Study 2305700 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise work rates (80‐90% of peak VO2) for 25 min/d
Number of subjects: 27
Study 2305700 — intervention group
Group type: COMPARATOR
Intervention: Low exercise work rates (40‐50% of peak VO2) for 50 min/d
Number of subjects: 27
Study 7022517 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 0
Study 7022517 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 30573151 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for nutrition policy implementation
Number of subjects: 595
Study 30573151 — intervention group
Group type: COMPARATOR
Intervention: Support for physical activity policy implementation
Number of subjects: 595
Study 30573151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition condition
Number of subjects: 595
Study 28536308 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF
Number of subjects: 815
Study 28536308 — intervention group
Group type: COMPARATOR
Intervention: Melanoma peptide vaccine
Number of subjects: 815
Study 28536308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 815
Study 28536308 — intervention group
Group type: COMPARATOR
Intervention: GM-CSF and/or peptide vaccine
Number of subjects: 815
Study 25886927 — intervention group
Group type: EXPERIMENTAL
Intervention: Triggered cell phone reminders and counseling using objective adherence data
Number of subjects: 120
Study 25886927 — intervention group
Group type: COMPARATOR
Intervention: No reminders or data-informed counseling
Number of subjects: 120
Study 23452375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (200 to 400 mg daily for 12 months)
Number of subjects: 252
Study 23452375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 23452375 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 252
Study 21575016 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 624
Study 21575016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 21575016 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead-in abstinence (n = 82)
Number of subjects: 624
Study 21575016 — intervention group
Group type: COMPARATOR
Intervention: No lead-in abstinence (n = 542)
Number of subjects: 624
Study 19524839 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching system (SEP) - Transbond Plus SEP, 3M Unitek
Number of subjects: 28
Study 19524839 — intervention group
Group type: COMPARATOR
Intervention: Conventional multi-step system (TBXT) - Transbond XT, 3M Unitek
Number of subjects: 28
Study 17149552 — intervention group
Group type: EXPERIMENTAL
Intervention: One Fleet enema 2 h pre-procedure (Group 1)
Number of subjects: 305
Study 17149552 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Fleet enemas (one on the evening prior and one 2 h pre-procedure) (Group 2)
Number of subjects: 305
Study 17149552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 30 ml orally 48 and 24 h prior to sigmoidoscopy, plus a single Fleet enema 2 h pre-procedure (Group 3)
Number of subjects: 305
Study 15529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel tip at full power (SS-FP)
Number of subjects: 45
Study 15529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond tip at full power (D-FP)
Number of subjects: 45
Study 15529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel tip at half power (SS-HP)
Number of subjects: 45
Study 15529135 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond tip at half power (D-HP)
Number of subjects: 45
Study 15529135 — intervention group
Group type: COMPARATOR
Intervention: Control group (only apically resected teeth)
Number of subjects: 45
Study 10573832 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFT (Linking the Interests of Families and Teachers) intervention
Number of subjects: 671
Study 10573832 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 671
Study 8917241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine (30 or 60 mg)
Number of subjects: 41
Study 8917241 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (20 or 37.5 mg)
Number of subjects: 41
Study 8917241 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both pseudoephedrine and phenylpropanolamine)
Number of subjects: 41
Study 1842943 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing at a rate of 30 beats/min
Number of subjects: 18
Study 1842943 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI pacing at a rate of 70 beats/min
Number of subjects: 18
Study 1842943 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological DDD or QT pacing
Number of subjects: 18
Study 1842943 — intervention group
Group type: COMPARATOR
Intervention: Physiological pacing vs standard ventricular pacing
Number of subjects: 18
Study 6626441 — intervention group
Group type: EXPERIMENTAL
Intervention: Alinidine 40 mg
Number of subjects: 5
Study 6626441 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.1 mg
Number of subjects: 5
Study 6626441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 30222511 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote international virtual network (RIVN) mentoring during tube thoracostomy insertion.
Number of subjects: 14
Study 30222511 — intervention group
Group type: COMPARATOR
Intervention: Unmentored tube thoracostomy insertion.
Number of subjects: 14
Study 30222511 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote telementoring (RTM) experience.
Number of subjects: 14
Study 30222511 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor opinion on safety of TT procedures.
Number of subjects: 14
Study 27916327 — intervention group
Group type: EXPERIMENTAL
Intervention: One-year increase in grade attainment in Uganda
Number of subjects: 1441
Study 27916327 — intervention group
Group type: COMPARATOR
Intervention: Grade attainment in Malawi
Number of subjects: 1441
Study 27916327 — intervention group
Group type: COMPARATOR
Intervention: Grade attainment in both countries
Number of subjects: 1441
Study 25581388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy with standard intra-abdominal pressure (IAP)
Number of subjects: 0
Study 25581388 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic donor nephrectomy with low intra-abdominal pressure (IAP)
Number of subjects: 0
Study 25581388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Number of subjects: 0
Study 25581388 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic colectomy
Number of subjects: 0
Study 22932716 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar (2.5 mg daily)
Number of subjects: 17779
Study 22932716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17779
Study 20417924 — intervention group
Group type: COMPARATOR
Intervention: Staples
Number of subjects: 180
Study 20417924 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 180
Study 18798083 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg oral administration)
Number of subjects: 0
Study 18798083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15621375 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (0.08‐8 ms, 2‐200 Hz)
Number of subjects: 30
Study 15621375 — intervention group
Group type: COMPARATOR
Intervention: Histamine iontophoresis (100 microC)
Number of subjects: 30
Study 15621375 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 30
Study 15115973 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (4 mg/kg per day)
Number of subjects: 20
Study 15115973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10604506 — intervention group
Group type: EXPERIMENTAL
Intervention: comprehensive geriatric assessment and post‐discharge home intervention
Number of subjects: 545
Study 10604506 — intervention group
Group type: COMPARATOR
Intervention: comprehensive geriatric assessment alone
Number of subjects: 545
Study 10604506 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 545
Study 8611058 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 80
Study 8611058 — intervention group
Group type: COMPARATOR
Intervention: Coping skills therapy (with placebo)
Number of subjects: 80
Study 8611058 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (with placebo)
Number of subjects: 80
Study 1960234 — intervention group
Group type: EXPERIMENTAL
Intervention: CPITN
Number of subjects: 52
Study 6347750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day clotrimazole treatment (200 mg once a day for 3 consecutive days)
Number of subjects: 0
Study 6347750 — intervention group
Group type: COMPARATOR
Intervention: 6-day clotrimazole treatment (100 mg once a day for 6 consecutive days)
Number of subjects: 0
Study 31246713 — intervention group
Group type: EXPERIMENTAL
Intervention: Running on a treadmill
Number of subjects: 38
Study 31246713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling on a cycle ergometer
Number of subjects: 38
Study 29735467 — intervention group
Group type: EXPERIMENTAL
Intervention: Small dose mifepristone
Number of subjects: 0
Study 29735467 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 0
Study 26432913 — intervention group
Group type: EXPERIMENTAL
Intervention: 50μg gE/AS01B formulation (HZ/su)
Number of subjects: 129
Study 24281294 — intervention group
Group type: EXPERIMENTAL
Intervention: PACSLAC-II
Number of subjects: 0
Study 24281294 — intervention group
Group type: COMPARATOR
Intervention: Preexisting pain assessment tools
Number of subjects: 0
Study 22898028 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone gel (1.1 mg/kg, PO, once daily)
Number of subjects: 35
Study 22898028 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone gel
Number of subjects: 35
Study 22898028 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 35
Study 20714379 — intervention group
Group type: EXPERIMENTAL
Intervention: Farcosolvin syrup (ambroxol 15 mg, theophylline 50 mg, guaiphenesin 30 mg per 5 mL)
Number of subjects: 100